Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1996-05-10
1997-06-10
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
A61K 3170
Patent
active
056375719
DESCRIPTION:
BRIEF SUMMARY
The present invention refers to the use of certain lignan derivatives for the preparation of pharmaceutical compositions for the treatment of certain diseases. More specifically, the invention refers to the use of certain acetals of podophyllotoxin-.beta.-D-glucopyranoside and 4'-demethylpodophyllotoxin-.beta.-D-glucopyranoside for the preparation of pharmaceutical compositions for the treatment or prophylaxis of states of amyloidosis. Furthermore, the invention refers to a method for treatment of a host afflicted with a state of amyloidosis.
Amyloidosis is the general name of states or diseases where amyloid is present in a host systemically or locally. The amyloid tissues are characterized by a content of amyloid, which is a collective name for a chemically heterogenous substance having certain characteristic properties. It is known that a common feature of amyloid is a specific secondary and tertiary structure wherein small proteins (molecular weight from 3000 to about 30,000 Daltons) are stacked on each other and are bonded to each other via hydrogen bonds to so-called beta-sheets, which give thin fibrils. These fibrils, which have a diameter of about 7.5 nanometers and can only be seen in an electron microscope, constitute the main material of all amyloid substance. A number of different proteins have the property of forming fibrils in this way, but only one single protein builds up the fibril in the particular deposition. The protein fibril constitutes the core of the amyloid substance and gives this substance some of its characteristic properties, such as a resistance against enzymatic and other degradation, and some staining properties which are important in practice. Other components are also present in all amyloid substance.
The amyloid fibrils are formed at the site of the incorporation. It is not yet known whether the fibrils are formed extracellularly or intracellularly. The proteins forming part of the fibrils can either be synthesized in cells at the site of the incorporation (local amyloidosis) or at some other site, such as the liver or the bone marrow, and be transported to the site of the incorporation by plasma (systemic amyloidosis).
A number of different types of amyloid are known, depending on the type of protein which forms the fibrils. However, all types of amyloid are regarded as pathological, and normally occurring amyloid fibrils have never been found. A consequence of this is that all amyloid is an expression of an abnormal formation of fibrils. It is not yet known why the amyloid fibrils are not degraded but are instead incorporated progressively. One explanation of this may lie in the strong intermolecular bonds in the fibril, and possibly also in a protective sheathing of proteoglycans. It may be noted that the amyloid hardly ever gives rise to any inflammatory reaction.
The pathogenetic importance of the amyloid substance lies to a large degree in the space which the substance occupies, with a consequent atrophy of the surrounding tissue. The amyloid, which is deposed between cells and between groups of cells and vessels, probably hinders the transport of nourishments and other substances. The cell membranes may be damaged by penetrating fibrils. Furthermore, the amyloid substance seems to affect the basal membranes, at least in the glomeruli, so that the filtering efficiency is degraded.
Amyloidosis has been observed in association with a number of diseases, such as certain mental illnesses, neurological diseases and collagenosis. Among the various types of mental illness in this connection may be mentioned Alzheimer's disease, senile dementia and multi-infarct dementia, and among the neurological diseases may be mentioned multiple sclerosis and head traumata. As an example of collagenosis may be mentioned rheumatoid arthritis. It has been found that amyloid appears both as a primary (S-AL) and a secondary (S-AA) phenomenon in addition to the main diagnosis in senile system amyloidosis (S-TTR) and other diseases. The amino acid sequence in the amyloid may varity depending
REFERENCES:
patent: 4788216 (1988-11-01), Leander et al.
Truedsson et al, Clinical and Experimental Rheumatology, 11:179-182 (1993).
Dahlqvist et al, British Journal of Rheumatology, 28:418-421 (1989).
Leander Kurt
Rosen Borje
Analytecon SA
Conpharm AB
Criares Theodore J.
LandOfFree
Use of lignan derivatives for the preparation of pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of lignan derivatives for the preparation of pharmaceutical , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of lignan derivatives for the preparation of pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-764682